The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Podzolkov V.I.

Sechenov First Moscow State Medical University of Healthcare Ministry of the Russian Federation, Moscow? Russia

Bragina A.E.

Kafedra fakul'tetskoĭ terapii #2 GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova;
Kafedra akusherstva i ginekologii GBOU DPO "Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia", Moskva

Osadchiy K.K.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

A fixed-dose lisinopril+amlodipine+rosuvastatin combination: prospects for its use in patients with hypertension and concomitant dyslipidemia

Authors:

Podzolkov V.I., Bragina A.E., Osadchiy K.K.

More about the authors

Journal: Therapeutic Archive. 2017;89(12): 133‑140

DOI: 10.17116/terarkh20178912133-140

Read: 5168 times

Download PDF (RU)
Contact the author
Table of contents

A FIXED-DOSE LISINOPRIL+AMLODIPINE+ROSUVASTATIN COMBINATION: PROSPECTS FOR ITS USE IN PATIENTS WITH HYPERTENSION AND CONCOMITANT DYSLIPIDEMIA
A FIXED-DOSE LISINOPRIL+AMLODIPINE+ROSUVASTATIN COMBINATION: PROSPECTS FOR ITS USE IN PATIENTS WITH HYPERTENSION AND CONCOMITANT DYSLIPIDEMIA

To cite this article:

Podzolkov VI, Bragina AE, Osadchiy KK. A fixed-dose lisinopril+amlodipine+rosuvastatin combination: prospects for its use in patients with hypertension and concomitant dyslipidemia. Therapeutic Archive. 2017;89(12):133‑140. (In Russ.)
https://doi.org/10.17116/terarkh20178912133-140

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Predictors of Enga­gement and Active participation of Patients with Unco­ntrolled Hype­rtension in the Tele­health Surveillance Program. Russian Journal of Preventive Medi­cine. 2024;(12):37-43
The role of quantitative body composition analysis in popu­lation in the asse­ssment and moni­toring of cardiovascular risk meta­bolic factors. Russian Journal of Preventive Medi­cine. 2024;(12):128-134
Effi­cacy and tole­rability of azilsartan combined with amlo­dipine and amlo­dipine mono­therapy and combinations of amlo­dipine with other angiotensin II rece­ptor blockers. Russian Cardiology Bulletin. 2024;(4-2):161-171
Risk factors and adve­rse outcomes of cardiovascular diseases in people with high normal blood pressure of the Ryazan region. (5-year prospective follow-up). Russian Journal of Preventive Medi­cine. 2025;(2):31-37
Diagnostics of hype­rtensive diso­rders in cardio-obstetrics: current state-of-affairs. Russian Journal of Human Reproduction. 2025;(1):63-77
Differentiated approach to the choice of agents for pathogenetic drug therapy in patients with alle­rgic rhinitis. Russian Rhinology. 2025;(1):18-26
Exploring the capa­bility of the cardiovascular risk evaluation using the vital functions inte­gral analysis. Russian Journal of Preventive Medi­cine. 2025;(3):53-59
Prevalence and role of elevated serum lipo­protein(a) in patients with myocardial infa­rction acco­rding to the Russian regi­ster of acute myocardial infa­rction REGION-MI. Russian Cardiology Bulletin. 2025;(1):39-48
On the path to personalized cardiology: prospects of precise asse­ssment of cardiovascular risks and predictive-prognostic diagnostics. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):206-215
Two years expe­rience of using alirocumab in patients with dyslipidemia. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):216-220
Abstract:

In Russia, target blood pressure (BP) levels are achieved in only 14.4% of men and in 30.9% of women. The need for combination therapy of hypertension is as high as 70.7%. There are well-known benefits of combined antihypertensive therapy allowing for higher efficiency and better tolerability. One of the current combinations is a combination of an angiotensin-converting enzyme inhibitor and a calcium antagonist, which have pronounced protective activity and metabolic neutrality. Fixed-dose combinations have substantial advantages over free ones, contributing to improving patient compliance with the used treatment regimen. Dyslipidemia is present in 60.7% of the hypertensive patients. Nonetheless, only 9.7% of Russian patients with coronary heart disease take statins and control of lipid levels remains very poor. The review discusses whether the use of the triple combination lisinopril + amlodipine + rosuvastatin is reasonable from the standpoint of evidence-based medicine. There are literature data suggesting the high value of this fixed-dose combination in the context of organ protection and the reduced risk of cardiovascular events.

Keywords:

hypertension
fixed-dose combination
lisinopril
amlodipine
rosuvastatin
cardiovascular risk
organ protection

Authors:

Podzolkov V.I.

Sechenov First Moscow State Medical University of Healthcare Ministry of the Russian Federation, Moscow? Russia

Bragina A.E.

Kafedra fakul'tetskoĭ terapii #2 GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova;
Kafedra akusherstva i ginekologii GBOU DPO "Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia", Moskva

Osadchiy K.K.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

Close metadata

References:

  1. Wald NJ and Law MR. A strategy to reduce cardiovascular disease by more than 80%. British Medical Journal. 2003;326(7407):1419. https://doi.org/10.1136/bmj.326.7404.1419
  2. Neaton JD, Wentworth D; for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,009 white men. Arch Intern Med. 1992;152:56-64.
  3. Chazova IE,Zhernakova Yu V1, Oshchepkova EV1, Shalnova SA, Yarovaya EB, Konradi AO, Boytsov SA, Kaveshnikov VS, Serebryakova VN, Trubacheva IA. Prevalence of Cardiovascular Risk Factors in Russian Population of Patients With Arterial Hypertension. Kardiologiia. 2014;10:4-12. (In Russ.) https://doi.org/10.18565/cardio.2014.10.4-12
  4. Boytsov SA, Luk’yanov MM, Yakushin SS, Martsevich SY, Vorobyov AN, Zagrebelny AV, Pereverzeva KG, Pravkina EA, Deev AD, Andreenko EY, Ershova AI, Meshkov AN, Myasnikov RP, Serdyuk SS, Kharlap MS, Bazaeva EV, Kozminsky AN, Moseychuk KA, Kudryashov EN. Cardiovascular diseases registry (RECVAZA): diagnostics, concomitant cardiovascular pathology, comorbidities and treatment in the real outpatient-polyclinic practice. Cardiovascular Therapy and Prevention. 2014;13(6):44-50. (In Russ.) https://doi.org/10.15829/1728-8800-2014-6-44-50
  5. Leonova MV, Shteinberg LL, Belousov YuB et al. Pharmacoepidemiology of arterial hypertension in Russia: the analysis of physicians acceptance (according to the results of PIFAGOR IV). Sistemnye gipertenzii. 2015;1:19-25. (In Russ.)
  6. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
  7. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36(3):646-661.
  8. Podzolkov VI. (ed) Arterial hypertension. Moscow: Medical information agency. 2016. (In Russ.)
  9. Gupta A, Poulter N. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive drugs: a meta-analysis. Hypertension. 2010;55:399-407. https://doi.org/10.1161/HYPERTENSIONAHA.109.139816
  10. Jamerson KA, Weber MA.,Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, for the ACCOMPLISH Trial Investigation. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N Eng J Med. 2008;359:2417-2428. https://doi.org/10.1056/NEJMoa0806182
  11. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219. https://doi.org/10.1097/01.hjh.0000431740.32696.cc
  12. Miyajima E, Shigemasa T, Yamada Y, Tochikubo O, Ishii M. Angiotensin II blunts, while an angiotensin-converting enzyme inhibitor augments, reflex sympathetic inhibition in humans. Clin Exp Pharmacol Physiol. 1999;26:797-802.
  13. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86:1182-1187 https://doi.org/10.1016/S0002-9149(00)01199-1
  14. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5(2):95-110.
  15. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens. 1992;6(2):85-90.
  16. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant. 1998;13(3):564-569.
  17. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510. https://doi.org/10.1161/01.CIR.102.13.1503
  18. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-2225. https://doi.org/10.1001/jama.292.18.2217
  19. Rackel R, Bope E (eds). Conn’s Therapy. Phyladelphia: WB Saunders, 2003.
  20. Messerli FH, Grossman E. Pedal edema--not all dihydropyridine calcium antagonists are created equal. Am J Hypertens. 2002; 15(11):1019-1020.
  21. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial — Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentrerandomised controlled trial. Lancet 2005;366:895-906. https://doi.org/10.1016/S0140-6736(05)67185-1
  22. Bakris G, Briasoulis A, Dahlof B, Jamerson K, Weber MA, Kelly RY, Hester A, Hua T, Zappe D, Pitt B; ACCOMPLISH Investigators. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol. 2013;112(2):255-259. https://doi.org/10.1016/j.amjcard.2013.03.026
  23. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC, Svetkey LP, Taler SJ, Townsend RR, Wright JT, Narva AS, Ortiz E. 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. https://doi.org/10.1001/jama.2013.284427
  24. Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998;351:28-31. https://doi.org/10.1016/S0140-6736(97)06209-0
  25. Pall D, Katona E, Juhasz M et al. Prevention of target organ damage with modern antihypertensive agents. Orv Hetil. 2006;147 (32):1505-1511.
  26. Nedogoda SV, Chumachek EV, Ledyaeva AA, Tsoma AV, Salasyuk AS. Comparative effectiveness of fixes-dose combinations of lisinopril/amlodipine and enalapril/hydrochlorothiazide. Cardiovascular Therapy and Prevention. 2013;12(2):25-29. (In Russ.) https://doi.org/10.15829/1728-8800-2013-2-25-29
  27. Ostroumova OD, Pervichko EI. Effect of the fixed-dose combination Ekvator on blood pressure level and cognitive functions in elderly patients with arterial hypertension. Sistemnye gipertenzii. 2013; 1:88-91. (In Russ.)
  28. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentrerandomised controlled trial. Drugs. 2004; 64(S2):43-60. https://doi.org/10.1016/S0140-6736(03)12948-0
  29. Jones PH, Davidson MH, Stein EA et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160. https://doi.org/
  30. Crouse JR, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH et al. METEOR Study Group. Effect of rosuvastatin on progression of carotid intimamedia thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344-1353. https://doi.org/10.1001/jama.297.12.1344
  31. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-1565. https://doi.org/10.1001/jama.295.13.jpc60002
  32. Ridker PM, Danielson E, Fonseca FA et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207. https://doi.org/10.1056/NEJMoa0807646
  33. Karpov YuA, Ljalina SV. Study TRIUMVIRATE: Reducing the Risk of Cardiovascular Events in Hypertensive Patients Using Triple Combination Antihypertensive and Lipid-Lowering Drugs. Kardiologija. 2015;9:10-15. (In Russ.) https://doi.org/10.18565/cardio.2015.9.10-15
  34. Blankova ZN, Aslanian NS, Smolianinova NG, Ageev FT. Treatment of patients with high cardiovascular risk: a modern view on combined therapy. Sistemnye gipertenzii. 2017;14(1):12-16. (In Russ.)
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.